Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase‐4 in patients with type 2 diabetes and non‐alcoholic fatty liver disease

2019 ◽  
Vol 73 (5) ◽  
pp. e13335 ◽  
Author(s):  
Yoshimasa Aso ◽  
Kanako Kato ◽  
Shintaro Sakurai ◽  
Haruka Kishi ◽  
Masanori Shimizu ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Sglt2 Inhibitor ◽  
Serum Levels ◽  
Alcoholic Fatty Liver ◽  
Dipeptidyl Peptidase 4 ◽  
Alcoholic Fatty Liver Disease

Dapagliflozin reduces hepatic and visceral fat in type‐2 diabetes patients with non‐alcoholic fatty liver disease

2021 ◽  
Author(s):  
Susrichit Phrueksotsai ◽  
Kanokwan Pinyopornpanish ◽  
Juntima Euathrongchit ◽  
Apinya Leerapun ◽  
Arintaya Phrommintikul ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Liver Disease ◽  
Fatty Liver ◽  
Visceral Fat ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease ◽  
Diabetes Patients

scholarly journals Non‐alcoholic fatty liver disease in type 2 diabetes – A specific entity?

2021 ◽  
Vol 41 (S1) ◽  
pp. 105-111
Author(s):  
Benjamin Schröder ◽  
Sabine Kahl ◽  
Michael Roden
Keyword(s):  
Type 2 Diabetes ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease
Sign in / Sign up

Export Citation Format

Share Document